key: cord-0734322-2x6evw1o authors: Maggiolo, Franco; Zoboli, Fabio; Arosio, Marco; Valenti, Daniela; Guarneri, Davide; Sangiorgio, Lorena; Ripamonti, Diego; Callegaro, Annapaola title: SARS‐CoV‐2 infection in persons living with HIV: a single center prospective cohort date: 2020-07-24 journal: J Med Virol DOI: 10.1002/jmv.26352 sha: c50bdfe9f2a73d0ab4f81e9dc2c8e702eb999f8c doc_id: 734322 cord_uid: 2x6evw1o BACKGROUND: Information about SARS‐CoV‐2 infection in HIV‐infected individuals is scarce. METHODS: In this prospective study, we included HIV‐infected individuals (PLWHIV) with confirmed SARS‐CoV‐2 infection and compared them with PLWHIV negative for SARS‐CoV‐2. RESULTS: we compared 55 cases of SARS‐CoV‐2 infection with 69 asymptomatic PLWHIV negative for SARS‐CoV‐2 RT‐PCR and/or serology. There was no significant difference between SARS‐CoV‐2 positive or negative patients for age distribution, gender, time with HIV infection, nadir CD4‐cell counts, type and number of co‐morbidities, current CD4 and CD8 counts and type of anti‐HIV therapy. Positive patients presented with a median of 3 symptoms (IQR 1‐3). Most common symptoms were fever (76%), dyspnoea (35%), anosmia (29%) non‐productive cough (27%), fatigue 22%) and ageusia (20%). Ten patients (18%) were completely asymptomatic. Four (7.2%) subjects died of COVID‐19. Factors significantly (P<0.05) associated with death included age and number of co‐morbidities, while time from HIV infection and lower current CD4 counts were significant only in univariate analysis. CONCLUSION: HIV‐infected individuals are not protected from SARS‐CoV‐2 infection or have a lower risk of severe disease. Indeed, those with low CD4 cell counts might have worse outcomes. Infection is asymptomatic in a large proportion of subjects and this is relevant for epidemiological studies. This article is protected by copyright. All rights reserved. On December 31, 2019 an outbreak of pneumonia was first reported in Wuhan, China, and soon after identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , and the disease due to this infection was named COVID-19. The increasing number of cases of COVID-19 world-wide, induced WHO to declare a pandemic [2] . Italy is one of the most affected Countries in Europe with 238.499 confirmed cases as of June 21, 2020 [3] . The Province of Bergamo with about 1.100.000 inhabitants and 14 .120 infected subjects is one of the focal areas of the Italian epidemic [3] . Very little is known about how persons living with HIV (PLWHIV) could react to SARS-CoV-2 infection. It has been postulated that HIV-infected individuals might be at This article is protected by copyright. All rights reserved. an increased risk because of the presence of comorbidities, lower CD4 cell counts, or unsuppressed virus [4] [5] [6] . Conversely, it has been suggested that immunosuppression might prevent or lower the severe cytokine storm observed in COVID-19 reducing its severity [7, 8] . Finally, antiretrovirals have been indicated as able to modify the risk of infection with SARS-CoV-2 and its clinical picture in PLWHIV [8, 9] . This uncertainty is due to the paucity of work on the topic, being available data based on small cases series [4, [10] [11] [12] [13] [14] , or on two larger cohorts either uncontrolled [8] or with controls untested for SARS-CoV-2 [6] . This is the first cohort study in which PLWHIV either symptomatic or not were tested for SARS-CoV-2. This is a cohort, single center, clinical, prospective study performed in a Province of Northern Italy highly hit by the SARS-CoV-2 epidemic. Aim of the study was to identify possible characteristics of PLWHIV that could correlate with the risk of acquiring SARS-CoV-2 infection and, in the case of infection, would influence the outcome. Since the beginning of the epidemic, data of all suspected or confirmed COVID-19 cases were recorded in a specific database linked to a common research project authorized by the local Ethical Committee. All patients gave their informed consent. Data for the present cohort study were extracted from this database. They were cross-linked with information from the outpatient clinic electronic health records. Data of patients not This article is protected by copyright. All rights reserved. admitted to the hospital were obtained by each patient during a visit performed in the first 15 days of June. All these patients subscribed an informed consent, too. Recorded variables were age, gender, comorbidities, HIV-specific variables such as year of HIV infection diagnosis, nadir and most recent (e.g. within 3 months from 1 st March 2020) CD4 cell counts, CD8 cell counts, CD4/CD8 ratios, HIV-RNA plasma levels, current antiretroviral therapy (ART). Clinical characteristics of COVID-19, and outcomes were recorded for SARS-CoV-2 positive patients. During the acute phase of the epidemics, Laboratory diagnosis of SARS-CoV-2 infection was done by RT-PCR with primer and probes targeting E, RdRp and N genes. Nasopharyngeal swabs or lower respiratory tract aspirates were tested only in individuals admitted to the hospital as public health authorities' regulations did not recommend tests in individuals with mild symptoms not admitted to hospitals. Later on, for specific categories (e.g. health-care workers) nasopharyngeal swabs were permitted. In all other cases, the diagnosis was achieved by means of serological tests. This article is protected by copyright. All rights reserved. Confirmed COVID-19 was defined by positive RT-PCR for SARS-CoV-2 in respiratory samples or a positive serological test. Suspected cases were those in individuals with clinical and radiological findings compatible with COVID-19, but whose RT-PCR results were inconclusive in the absence of any other proven cause (e.g. Pneumocystis jiroveci pneumonia). The severity of disease was scored based on the worse type of respiratory support needed (e.g. invasive mechanical ventilation, noninvasive mechanical ventilation, oxygen mask). Confirmed SARS-CoV-2 negative patients were asymptomatic, with either RT-PCR or serology or both tests negative. No sample size was calculated given that all known individuals with a diagnosis of COVID-19 were included. Continuous variables are presented as median and interquartile range (IQR). Categorical variables are expressed as number of patients (percentage). Comparisons were assessed by using the Mann-Whitney U test for continuous variables, whereas categorical variables were assessed by chi-square test. We used a binary logistic regression model to explore the factors associated with COVID-19 diagnosis and the risk of death. Statistical significance was defined as a two-sided P-value <0.05. All statistics were done with SPSS Statistics for Windows, version 17.0. This study has no funder. This article is protected by copyright. All rights reserved. At our center, 2898 PLWHIV are currently in active follow-up. Among these, we identified 55 cases of SARS-CoV-2 infection either by RT-PCR test (16 cases, 29%), serology (33 cases, 60%) or clinical grounds (6 cases, 11%) when tests were negative, the clinical picture was highly suggestive and no other explanation was found. We RT-PCR was negative for neurotropic viruses, but was positive for SARS-CoV-2. Two months later SARS-CoV-2 was negative in CSF, but he did not develop an immunological response to the virus. In the control group, 4 patients showed viral blips (< 200 copies/ml) at last control. One subject had an HIV-RNA of 55.100 copies/ml. He This article is protected by copyright. All rights reserved. was the only patient that, in the negative group, was admitted, in April, to the COVID-19 sub-intensive unit because of fever, respiratory distress, and a patchy ground glass alteration at chest radiology. He tested positive for HIV during the hospital stay, his nasal swabs were negative for SARS-CoV-2 and RT-PCR was negative on bronco-aspirate that, conversely, turned positive for Pneumocystis jiroveci. One month later, his SARS-CoV-2 serology was negative, too. Amongst positive cases only 15 (27%) were admitted to the hospital because of COVID-19. Positive patients presented with a median of 3 symptoms (IQR 1-3). The most common symptoms were fever (76% of cases), dyspnoea (35%), anosmia (29%) nonproductive cough (27%), fatigue 22%) and ageusia (20%). However, 10 patients (18%) were completely asymptomatic. In positive subjects, we evaluated the severity of diseases. Overall, 11 subjects (20%) required more intensive respiratory support. Factors associated with the need of invasive mechanical ventilation or c-PAP included the number of co-morbidities (P = 0.02) and age (P = 0.004). Only 11% of subjects without co-morbidities required invasive mechanical ventilation or c-PAP compared to 18% of those with 1 comorbidity and 41% of those with two or more co-morbidities. Median age in patients requiring at the most oxygen mask was 53 years (IQR 47-57) and raised to 62 years (IQR 57-66) in those who needed more intensive support. In the multivariable model, however, only age (P = 0.023) retained a statistical significance. COVID-19 had a fatal outcome in 4 (7.2%) subjects. According to univariate analysis, factors significantly associated with death included age, time from HIV infection, number of current co-morbidities and current CD4 counts (table 2) . However, only age This article is protected by copyright. All rights reserved. and the number of co-morbidities were statistically associated with the outcome in the multivariate model. Our study addresses some of the unknown aspects of SARS-CoV-2 infection in PLWHIV. A distinctive aspect of our study is the fact that all included patients were tested for SARS-CoV-2 making it one of the largest cohort of individuals with HIV and demonstrated SARS-CoV-2 co-infection. Interestingly, none of the classical variables linked to HIV infection such as nadir CD4 cell counts, time of HIV infection or current CD4 counts were predictive of the risk of acquiring SARS-CoV-2 infection, nor the use of specific antiretrovirals resulted having a protective effect as previously reported [8, 9] . It can be postulated that in PLWHIV, as in the general population, other variables not HIV-related such as work activities or adherence to lock-down and social-distancing procedures might be prominent in determining the risk of infection [13] . Previous studies have suggest that immunosuppression and low CD4 cell counts might protect HIV-infected individuals from developing the cytokine storm observed in patients with COVID-19 [7, 8, 14] . In our casuistry, the seriousness of the infection was not influenced by the current immunological situation nor by the previous immunedepressive status as measured by the nadir CD4 cell counts. As a matter of fact, patients with a fatal outcome presented with lower CD4 counts, even if the difference was not statistically significant when analyzed according to a multivariate model. These findings confirm previously reported observations [6, 15] . This article is protected by copyright. All rights reserved. Most previous studies in PLWHIV concentrated on patients admitted to the hospital because of COVID-19 [6, 8, 15] . In our cohort, most of the included patients were not admitted to the hospital, testifying that, even in HIV positive subjects, SARS-CoV-2 may present as a mild diseases not requiring hospital admission or intensive care [18, 19] . As a matter of fact, the proportion of asymptomatic patients resulted quite high (18%). Such a value counting for almost a fifth of the potentially infected subjects needs to be taken into account in future analysis of the incidence of SARS-CoV-2 in HIV infected subjects [19] and potentially strengths the use of serological tests that allowed us to detect subjects with mild symptoms or even without any symptom. Our study has several limitations. First, the small number of individuals prevents us from generalizing our results, also because obtained in a highly epidemic area and therefore not necessarily applicable in places with a different prevalence. Second, the small sample does not allow us to definitively establish the role of immune status or the presence of comorbidities in the clinical presentation and outcomes. Third, as stated, some bias may exist in the rate of infection because local recommendations restricted confirmatory testing. Although we included all the HIV-infected individuals with documented SARS-CoV-2 infection, the high rate of asymptomatic patients we found raises the doubt that more unknown subjects could have been infected. The two specific cases we report in the results stress the risk of misdiagnosis, especially at the beginning of the epidemic and the importance of extended testing even if in extremely immune-depressed patients the immunological response may fail to mount. In conclusion, none of the parameters classically used to define immune suppression or risk of immune impairment in HIV positive subjects does correlate with the risk of acquiring SARS-CoV-2 infection. Although low CD4 counts were not associated with This article is protected by copyright. All rights reserved. the positivity for SARS-CoV-2, relative immunosuppression did seem to affect disease severity, and it might be associated with adverse outcomes. By contrast, there was no evidence that any specific antiretroviral drug affected SARS-CoV-2 infection or COVID-19 severity. The disease may cover a vast range of clinical pictures, being almost one fifth of infected individuals asymptomatic. Variables already described for the general population as risk factors for a more severe disease such as advanced age and the presence of multiple co-morbidities do apply to PLWHIV, too. FM received research grants from Gilead, ViiV, Jannsen and acted as member of advisory board for Gilead, ViiV, Jannsen and Merck. All other no conflict. This article is protected by copyright. All rights reserved. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance Director-General's opening remarks at the media briefing on COVID-19-11 Italian Ministry of Health (Ministero della Salute) Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city Reply to Comments on "Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort Inflammation, immune activation, and antiretroviral therapy in HIV Clinical features and outcomes of HIV patients with coronavirus disease 2019 Triphosphates of the two components in DESCOVY and TRUVADA are inhibitors of the SARS-CoV-2 polymerase COVID-19 in patients with HIV: clinical case series A Case Series of Five People Living With HIV Hospitalized With COVID-19 in Early Virus Clearance and Delayed Antibody Response in a Case of COVID-19 With a History of Co-Infection With HIV-1 and HCV Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers coinfection: A retrospective, record based, case series from South India Clinical features and outcomes of four HIV patients with COVID-19 in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients COVID-19 and HIV co-infection an emerging consensus Clinical outcomes and prognosis of patients with HIV and SARS-CoV-2 coinfection This article is protected by copyright. All rights reserved.